{"brief_title": "A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients", "brief_summary": "This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).", "condition": ["HIV Infections"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Tenofovir DF", "Tenofovir alafenamide"], "description": ["Tenofovir DF tablet administered orally once daily", "Tenofovir alafenamide tablet(s) administered orally once daily"], "arm_group_label": ["Tenofovir DF", "Tenofovir alafenamide 50 mg", "Tenofovir alafenamide 150 mg"], "other_name": ["Viread\u00ae", "GS-7340"], "criteria": "Inclusion Criteria - HIV-1 RNA levels greater than or equal to 30,000 copies/mL - CD4 count greater than or equal to 200 cells/mm3 - Serum creatinine <1.5 mg/dl - Hepatic transaminases less than or equal to 2.5 times the upper limit of normal - Total bilirubin less than or equal to 1.5 mg/dL - Adequate hematologic function - Serum amylase less than or equal to 1.5 times the upper limit of normal - Serum phosphate greater than or equal to 2.2 mg/dL - Not pregnant Exclusion Criteria - Prior treatment with antiretroviral therapy - Immunization within 30 days of study entry - A new AIDS defining condition within 30 days of study entry - Receiving nephrotoxic agents, probenecid, chemotherapeutic agents, corticosteroids, interleukin-2", "gender": "All", "minimum_age": "18 Years", "maximum_age": "65 Years", "healthy_volunteers": "No", "keyword": "treatment naive", "mesh_term": ["HIV Infections", "Tenofovir"], "id": "NCT00036634"}